Allarity Therapeutics Future Growth
Future criteria checks 0/6
Allarity Therapeutics is forecast to grow earnings and revenue by 2% and 66.4% per annum respectively while EPS is expected to grow by 35.4% per annum.
Key information
2.0%
Earnings growth rate
35.4%
EPS growth rate
Biotechs earnings growth | 30.8% |
Revenue growth rate | 66.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 28 Mar 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 49 | -15 | N/A | N/A | 1 |
12/31/2024 | N/A | -15 | N/A | N/A | 1 |
12/31/2023 | N/A | -14 | N/A | N/A | 1 |
3/31/2023 | N/A | -20 | -14 | -14 | N/A |
12/31/2022 | N/A | -21 | -17 | -17 | N/A |
9/30/2022 | N/A | -35 | -19 | -19 | N/A |
6/30/2022 | N/A | -29 | -18 | -18 | N/A |
3/31/2022 | N/A | -28 | -18 | -18 | N/A |
12/31/2021 | N/A | -27 | -15 | -15 | N/A |
9/30/2021 | -1 | -12 | -13 | -13 | N/A |
6/30/2021 | -1 | -12 | -11 | -11 | N/A |
3/31/2021 | N/A | -7 | -8 | -8 | N/A |
12/31/2020 | N/A | -7 | -7 | -7 | N/A |
9/30/2020 | 1 | -16 | -7 | -7 | N/A |
6/30/2020 | 1 | -17 | -8 | -8 | N/A |
3/31/2020 | 0 | -20 | -10 | -10 | N/A |
12/31/2019 | 0 | -20 | -11 | -11 | N/A |
9/30/2019 | 0 | -11 | -11 | -10 | N/A |
6/30/2019 | 1 | -8 | -9 | -9 | N/A |
3/31/2019 | 1 | -4 | -7 | -6 | N/A |
12/31/2018 | 1 | -2 | -4 | -4 | N/A |
9/30/2018 | 2 | -1 | -2 | -2 | N/A |
6/30/2018 | 1 | -1 | -2 | -2 | N/A |
3/31/2018 | 2 | -4 | 1 | 0 | N/A |
12/31/2017 | 1 | -5 | -1 | -1 | N/A |
9/30/2017 | 1 | -6 | -3 | -3 | N/A |
6/30/2017 | 1 | -6 | -3 | -3 | N/A |
3/31/2017 | 0 | -4 | -6 | -5 | N/A |
12/31/2016 | 0 | -4 | N/A | -4 | N/A |
9/30/2016 | 1 | -3 | N/A | -4 | N/A |
6/30/2016 | 1 | -2 | N/A | -4 | N/A |
3/31/2016 | 1 | -2 | N/A | -3 | N/A |
12/31/2015 | 0 | -1 | N/A | -2 | N/A |
12/31/2014 | 0 | 0 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: C6D0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: C6D0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: C6D0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: C6D0 is forecast to have no revenue next year.
High Growth Revenue: C6D0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if C6D0's Return on Equity is forecast to be high in 3 years time